
Excited to be back in Brussels, where I did part of my medical training, for #EMUC26
✓Professor of Prostate and Bladder Cancer Research. Interests: from novel diagnostics to care of advanced disease and novel trial design

Excited to be back in Brussels, where I did part of my medical training, for #EMUC26

Yet another positive diet, exercise, lifestyle trial....for men on ADT at high-risk of toxicity. The STAMINA RCT - thelancet.com/journals/lanon…

Back in 🇬🇧 but still able to listen to @nickva1 presenting @ASTRO_org #ASTRO26 @royalmarsdenNHS @EmmaHall71 No surprises here, patients have better sexual outcomes after SBRT compared to prostatectomy



I never viewed it as in any way clinically relevant. It’s just a way of counting relapses consistently for trials. Threshold for imaging should be driven by the imaging you have available. Plus the relevant pathology etc.

Doctors hail drug that spares bladder cancer patients ‘life-changing’ surgery | Cancer research | The Guardian. Great to see our RADio trial highlighted by guardian. Study investigated addition of Durvalumab to concurrent chemo RT. @prof_nick_james theguardian.com/science/2026…

Would be interesting to do this piece of research. However, as per my previous comments, PROTEUS has compared 2 non standard approaches with no SOC control so hard to make sense of it.

We have a number of professors of statistics on the author list and the paper has passed through peer statistical review at a high impact journal. I cannot comment on the specifics of the stats comments in this post but am confident in my co-authors’ knowledge in this area.


New data in @Annals_Oncology: A target trial emulation of >229K obese, nondiabetic adults shows GLP-1RA use is associated with a 41% reduction in obesity-associated cancers compared to lifestyle modifications alone (HR 0.59). - Congratulations to Aparna Kamat, Arthur Hsu, @pedroramirezMD & entire @MethodistHosp team annalsofoncology.org/article… @SGO_org

Delighted that our STAMPEDE paper on abiraterone therapy selection with MMAI in high risk M0 HSPC now out. kwnsfk27.r.eu-west-1.awstrac…

80% disease free survival at 1 year in bladder preserving Rx for MIBC using durvalumab and chemoradiotherapy. A significant step up from historical controls @Prof_Nick_James

Exactly, only around half, yet still looks v similar to other groups’ TMT data. A subgroup had biopsy only and still did fine. We presented this at ESMO a while ago (but not published sorry)

The data showing ⬇️outcomes when complete TURBT not done is almost certainly a surrogate marker of more advanced disease, which not surprisingly does worse. Appreciate @Prof_Nick_James sharing their experience. An extra procedure + creation of more hypoxia does seem low value.

Today’s decision from the Health Secretary on prostate cancer screening is a missed opportunity - too timid, too slow, and lacking the bold ambition that we so desperately wanted to see. As I set out last week, I fundamentally disagree with the National Screening Committee’s advice on a future screening programme for prostate cancer, which is far too narrow. I strongly believe that if we are really to get on top of prostate cancer - the most common cancer in British men - then a proper, targeted screening programme for all those at higher risk is needed… and needed now. I welcome expanded provision of focal therapy, which I benefited from last year with my own cancer; this must be an urgent priority to make available across the NHS. And the recognition that more work is needed to screen at risk groups, such as black men, is important. But this was an opportunity for bold, decisive, life-saving action - action that would help save the heartache of too many families losing a loved-one to this disease. That, sadly, has been missed. We will continue the campaign to urge the Government to go further, faster and put in place a progressive policy that includes a proper screening programme for the most at-risk men.